Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Phase 1 RCC Vaccine Is Safe, But Lacks Clinical Response
RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells, genetically modified tumor cells, and peptides. -
First-Ever Prospective Trial in Pediatric RCC Reports Results
The prospective study showed that after 4 years, complete resection of the tumor for children with local lymph node involvement (no metastasis) delivered an overall survival rate of 91.4%. -
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire. -
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
UROLOGIC CANCERS NEWS
New Dosing Option Approved for Imfinzi in NSCLC, Bladder Cancer
No Benefit to Modified Dosing of Lenvatinib-Everolimus in Advanced RCC
Phase 2 Study Initiated for HIF-2α Agent in Relapsed/Refractory RCC
Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC
Phase 3 Trial of Nivolumab With or Without Ipilimumab for Localized RCC After Nephrectomy
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Urologic Cancers
